NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Delcath Systems, Inc. (DCTH) Stock Analysis

Delcath Systems, Inc. (DCTH) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DCTH

$14.70

−$0.06 (−0.41%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DCTH with… →

DCTH Key Statistics

As of Oct 21, 2026
Trading
Open
$14.75
Previous Close
$14.76
Day's Range
14.57–14.91
52-Week Range
8.12–17.42
Volume
277.76K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$510.07M
P/E Ratio
1,470.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
326.67
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.60
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.35
EPS (ttm)Profit attributable to each share over the last twelve months.
0.01
Financials (FY)
Revenue (FY)
$85.23M+129.08%
Net Income (FY)
$2.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.70M
1-Year Return
+29.12%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
470.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DCTH closed at $14.70, +29.12% over 1 year.

Delcath Systems, Inc. (DCTH) has a market capitalization of $510.07M.

In fiscal 2025, DCTH reported revenue of $85.23M.

DCTH Stock Return by Calendar Year

Delcath Systems, Inc. (DCTH) return since May 2018: what $10,000 became

1 year
$10,000 $12,912
+29.12%
5 years
$10,000 $14,540
+45.40%
Since May 2018
$10,000 $156
−98.44%

If you had invested $10,000 in Delcath Systems, Inc. (DCTH) at the close on May 3, 2018, the earliest close on record here, it would have been worth $156 at the close on October 21, 2026: −98.44% in total, −38.84% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+45.54%
2025−16.11%
2024+189.42%
2023+15.56%
2022−53.55%
2021−56.75%
2020−15.67%
2019−89.16%
2018 (partial year)−79.26%

As of October 21, 2026.

DCTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$85.23M$2.70M3.2%
2024$37.21M−$26.39M−70.9%
2023$2.07M−$47.68M−2,308.9%
2022$2.72M−$36.51M−1,342.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$85.23M$73.43M$660.00K$2.70M3.2%
2024$37.21M$31.02M−$12.41M−$26.39M−70.9%
2023$2.07M$1.43M−$38.18M−$47.68M−2,308.9%
2022$2.72M$2.03M−$33.85M−$36.51M−1,342.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DCTH Valuation vs Medical Devices Median

Median of 145 stocks
MetricDCTHMedical Devices medianvs median
P/E1,470.0027.0854.3x the median
P/S ratio5.352.53111% above
Profit margin0.56%−14.78%15.3 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Delcath Systems, Inc. (DCTH) is capitalised at $510.07M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 156 employees.

DCTH last closed at $14.70 on October 21, 2026. That is −$0.06 (−0.41%) against the previous close. Over the past 52 weeks the price has ranged from $8.12 to $17.42. The latest close sits 81.03% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $85.23M. Against the prior fiscal year total of $37.21M, that is a change of +129.08%. The same year closed with net income of $2.70M. Profit margin runs at 0.56%. That is 15.3 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to 0.01.

Across the 4 fiscal years on file, revenue moves from $2.72M in 2022 to $85.23M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 1,470 times earnings. That is 54.3 times the Medical Devices median of 27.08. On forward earnings the ratio is 326.67. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.6. The price-to-sales ratio is 5.35. On price-to-sales that is 111.32% above the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

The trailing one-year total return is +29.12%. Measured over 5 years, that is +7.77% a year compounded. The reported beta is 0.6. Daily returns over the trailing 8 years annualize to a volatility of 98.47%.

Growth & Income

No dividend is on file for DCTH.

So far in 2026 the total return is +45.54%. Across the complete calendar years on file, 2024 returned +189.42% and 2019 returned −89.16%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Delcath Systems, Inc. (DCTH) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Delcath Systems, Inc. DCTH $510.07M 1,470.0
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Delcath Systems, Inc. trades at a P/E of 1,470.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Visit website →